In eight randomized controlled trials involving 7491 patients with type 2 diabetes mellitus (T2D) [178], compared with GLP-1 RAs, insulin, and the placebo groups, body weight and blood pressure were reduced in the tirzetapide-treated groups of overweight/obese T2DM patients, which was dose-dependent. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.